Caribou Biosciences, Inc., one of a handful of biotechs working on therapies based around gene editing, is at a pivotal point as it gears up for clinical trials of its CRISPR-based technology.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh